HeartLiNC: a programme led by Firalis to predict heart failure after myocardial infarction
HeartLiNC brings Firalis together with Seoul National University Hospital, QuantaMatrix, CHU de Toulouse and SimplicityBio.
Media
SAFE-T liver-safety biomarkers receive FDA and EMA letters of support
The IMI SAFE-T consortium, launched by Firalis in 2009, announced that the FDA and the EMA issued letters of support for new liver-safety biomarkers.
Media enquiries